Navigation Links
Antibiotic therapy reduces mortality by 68 percent in hemodialysis patients
Date:7/2/2014

DETROIT An antibiotic therapy known to reduce catheter-related bloodstream infections in hemodialysis patients has been shown for the first time to reduce mortality, according to a Henry Ford Health System study.

Researchers found that a low-dose "lock" solution of gentamicin/citrate reduced mortality by 68 percent compared to a solution of heparin, a blood-clotting therapy long considered the standard of care. Additionally, the gentamicin/citrate solution was associated with a 73 percent reduction in bloodstream infections compared to the heparin treatment.

Bloodstream infections are a leading cause of hospitalization and death in hemodialysis patients.

The findings are published online in the Clinical Journal of the American Society of Nephrology at http://bit.ly/1nZlCpd, and will appear in the journal's July print edition. An editorial accompanies the study.

Jerry Yee, M.D., division head of Nephrology and Hypertension at Henry Ford and the study's senior author, says the findings suggest the antibiotic therapy is a potential game-changer for hemodialysis treatment.

"Advances in treatment have been elusive over the years. Perhaps our study can be a starting point to change the paradigm as a standard of care," Dr. Yee says. "The gentamicin/citrate solution was shown to be both safe and effective."

For their prospective, observational study involving 749 patients from September 2008 to June 2011, researchers compared the two therapeutic solutions. There were 427 patients in the heparin study arm and 322 in the gentamicin/citrate arm. The solutions were administered using an antibiotic locking-technique that prevents catheter clotting and reduces infection.

Multiple studies have shown the benefit of using an antibiotic locking strategy for reducing bloodstream infections. However, the Centers for Disease Control and Preventi
'/>"/>

Contact: David Olejarz
David.Olejarz@hfhs.org
313-874-4094
Henry Ford Health System
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Researchers find evidence of banned antibiotics in poultry products
3. Study Finds Antibiotics Best for Appendicitis
4. FDA Seeks to Limit Antibiotics in Animal Feed
5. Probiotic Products May Prevent Antibiotic-Linked Diarrhea
6. Study Links Antibiotic to Slight Rise in Heart Patients Death Risk
7. Study shows antibiotic improves respiratory function in lung transplant patients
8. Antibiotic-Resistant Gonorrhea Spreading: WHO
9. A non-antibiotic approach for treating urinary tract infections
10. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
11. Study examines role of seasonal prescribing changes in antibiotic resistance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibiotic therapy reduces mortality by 68 percent in hemodialysis patients
(Date:7/24/2014)... (PRWEB) July 24, 2014 Becker's Hospital ... "100 Hospitals and Health Systems With Great Oncology Programs." ... in terms of quality patient care, cancer outcomes and ... hospitals for inclusion based on rankings and awards they ... following awards were considered as part of the criteria ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The European Omega ... omega 3 & structured lipids market in Europe with analysis ... from around $670.37 million in 2012 to $989.91 million by ... , Browse through the TOC of the European omega 3 ... the in-depth analysis provided. This also provides a glimpse of ...
(Date:7/24/2014)... 24, 2014 The European air and missile ... 2014, and is expected to register a CAGR of 8.06%, ... Russia, and turkey are the major spenders in the region ... extended air defense program and multinational (MEADS) program, which has ... through the TOC of the Europe air and missile defense ...
(Date:7/24/2014)... p53 refers to cancer biology, and the functions of ... in detail. Furthermore, also in cancer biology, it is ... cells in order to block their metabolism and prevent ... research on p53 attempts to unveil its functions in ... cells. Recent studies with cell cultures have demonstrated that ...
(Date:7/24/2014)... malaria parasite becomes resistant to an investigational drug. ... in St. Louis, also is relevant for other ... The study appears July 24 in Nature ... that causes malaria, make a class of molecules ... organisms healthy, whether plants, animals or bacteria. In ...
Breaking Medicine News(10 mins):Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
... MEDI3) (MEDIAL SAUDE) announces the following webcast:, What: Medial Saude ... 2008 @ 12:00 PM EDT, Where: http://prnewswire.isat.com.br/?palestra_id=305 , How: ... the address above., ... Toll-free from the US: (1 800) 860-2442; ...
... might be swaying clinicians , , WEDNESDAY, May ... overdiagnosed, say researchers at Rhode Island Hospital and ... half of patients previously diagnosed with bipolar disorder ... -- the Structured Clinical Interview for DSM-IV (SCID). ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... new data analysis that was conducted to examine ... boys and girls aged 6 to 12 years ... findings from the analysis reaffirmed that DAYTRANA has ...
... Agrees to $2.3 million fine, CARMEL, Ind., ... ),today announced a settlement among state insurance regulators ... Insurance (CSHI) Company,and Bankers Life and Casualty Company. ... by Pennsylvania, Illinois,Indiana, Texas and Florida related to ...
... Vail Valley ... Medical Center, VAIL, Colo., May ... today the appointment of the new President,and CEO, John H. Cassin. Cassin ... Medical Center., "John brings great leadership experience and an engaging personal,style, ...
Cached Medicine News:Health News:UAB first in US to offer speedier precise cancer radiotherapy 2Health News:Bipolar Disorder Might Be Overdiagnosed 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 3Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Vail Valley Medical Center Board of Directors Announces Appointment of New President & CEO, John Cassin 2
(Date:7/24/2014)... ANGELES , July 24, 2014  Bruin ... devices, announced today that after two weeks of ... throughout the European Union, it gained substantial concurrence ... moisture) and the clinical utility of BBI,s SEM ... over 90 percent of the respondents drawn from ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
(Date:7/24/2014)... , July 24, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... will release second quarter financial results after market close ... a webcast and conference call the same day at ... financial results and provide a corporate update. ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2
... Dec. 14, 2010 Biodel Inc. (Nasdaq: BIOD ... the company,s Chief Scientific Officer.  Dr. Steiner is a co-founder ... board of directors.  He served as Biodel,s chairman, president and ... March 2010 when Dr. Errol De Souza was named the ...
... announces that a new market research report is ... Pharmaceuticals Research Review http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html ... has accentuated the fault lines already dividing the ... pharma companies, coupled with the patent expiration precipice, ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
Karlin XL Magnum Ring Curettes, extra long (XL) curettes, black handles, lightweight. Length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Hardy Curettes, bayonet, working distance 4 3/4" (120 mm), total length 9 1/2" (241 mm), tip width 3 mm....
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Medicine Products: